• 

  Pharma stocks under pressure, tank over 10 per cent as Trump hints at 'never seen before' tariffs

  April 04, 2025 11:42 IST

  Cipla Share Price, Sun Pharma Share Price: Earlier on Thursday, shares of pharma companies surged 7 per cent after the Trump administration exempted pharmaceuticals from reciprocal tariffs.

• 

  Cipla recalls six batches of bronchospasm treatment inhalation aerosol in US

  World | July 07, 2023 14:36 IST

  Out of an abundance of precaution, Cipla further said the specified six batches manufactured using the same lot of valves are being recalled.

• 

  VIDEO: Cipla gets DCGI nod to import Modernas COVID vaccine

  News | June 30, 2021 8:15 IST

  Drugs Controller General of India (DCGI) granted permission to Mumbai-based pharmaceutical firm Cipla to import Moderna COVID-19 vaccine for India.

• 

  Cipla gets DCGI nod to import Moderna's Covid vaccine for emergency use in India: Centre

  India | June 29, 2021 21:30 IST

  Mumbai-based pharmaceutical firm Cipla has received the Drugs Controller General of India (DCGI) nod to import Moderna’s COVID-19 vaccine for restricted emergency use in India, sources told news agency PTI.

• 

  Moderna seeks regulatory approval for Covid-19 vaccine in India; Cipla applies for import

  India | June 29, 2021 12:54 IST

  Moderna seeks regulatory approval for its COVID-19 vaccine in India. Cipla has also applied for authorisation to import and marketing of Moderna jabs in the country.

• 

  COVID: Cipla launches 'ViraGen' RT-PCR test

  Business | May 20, 2021 15:40 IST

  ViraGen is Cipla's third offering in the Covid testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.

• 

  Cipla inks pact with Eli Lilly to produce, sell COVID-19 treatment drug

  Business | May 10, 2021 11:56 IST

  This collaboration is a step further in the company's efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.

• 

  Cipla launches antibody detection kit for coronavirus in India

  Business | October 28, 2020 19:29 IST

  Drug firm Cipla on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).

• 

  Equity indices close in the green, Cipla gains 9.5 pc

  News | August 10, 2020 18:31 IST

  Equity benchmark indices shaved off early gains but ended in the positive terrain on Monday with pharma stocks leading the rally.

• 

  Cipla Q1 net profit up 27 pc at Rs 566 cr

  Business | August 07, 2020 19:44 IST

  Drug firm Cipla on Friday reported a 26.58 per cent rise in its consolidated net profit to Rs 566.04 crore for the quarter ended June on the back of robust sales.

• 

  Collaborating with govt agencies to develop treatment for COVID-19: Cipla

  Business | August 05, 2020 15:33 IST

  Besides scaling up production of medicines that show potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up manufacturing of drugs for chronic ailments such as asthma, COPD, among others, Hamied said.

Advertisement
• 

  Sensex cracks by 335 points but pharma stocks outperform

  News | July 30, 2020 18:56 IST

  Equity benchmark indices swung nearly 1 per cent lower during the afternoon session on July 30 ahead of the expiry day of monthly futures and options contracts.

• 

  Hyderabad's Avra Labs to make Favipiravir for Cipla's Ciplenza

  Business | July 27, 2020 15:06 IST

  Hyderabad-based Avra Laboratories Pvt Ltd announced on Monday that it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Favipiravir Active Pharmaceutical Ingredient (API) for treatment of COVID-19.

• 

  Cipla gets nod to launch affordable Favipiravir in India for treatment of COVID-19 patients

  India | July 24, 2020 17:54 IST

  Pharmaceutical firm Cipla is set to launch COVID-19 drug Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process. Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India.

• 

  Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets

  Business | July 20, 2020 11:43 IST

  The the civil action filed by Cipla in the U.S. District Court for the District of Delaware in January 2019 has been resolved as between Cipla and Amgen Inc, the drug major said on Monday (20 July).

• 

  Cipla launches generic version of remdesivir in India

  Business | July 08, 2020 21:24 IST

  Pharma major Cipla on Wednesday said it has launched its generic version of antiviral drug remdesivir at a price which is among the lowest globally and is looking to supply over 80,000 vials within the first month.

• 

  Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial

  Business | June 23, 2020 21:03 IST

  Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.

• 

  Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID-19 fight, say medical experts

  India | June 22, 2020 23:06 IST

  With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".

• 

  Cipremi: Cipla also launches COVID-19 treatment medicine, all you need to know

  Fyi | June 22, 2020 12:34 IST

  Cipla, an Indian multinational pharmaceutical and biotechnology company, has launched its own antiviral drug named Cipremi for treating COVID-19 patients.

• 

  Cipla launches generic remdesivir for COVID-19 patients

  India | June 21, 2020 23:28 IST

  Homegrown pharma major Cipla Ltd announced the launch of its generic version of remdesivir, which has been authorised for emergency use in the treatment of COVID-19 patients by the USFDA, under its brand name Cipremi.